Delstrigo is an antiviral medicine used to treat adults and adolescents from 12 years of age weighing at least 35 kg who are infected with human immunodeficiency virus type 1 (HIV\-1\), a virus that causes acquired immune deficiency syndrome (AIDS). The medicine is only used in patients where the virus has not developed resistance to medicines that work in the same way as Delstrigo’s active substances. It is only used in adolescents if other HIV medicines without tenofovir disoproxil cannot be used because of side effects. Delstrigo contains the active substances doravirine, lamivudine and tenofovir disoproxil.
Therapeutic Indication
Delstrigo is indicated for the treatment of adults infected with HIV 1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir. Delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with HIV\-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.
Therapeutic Area (MeSH)
ATC Code
J05AR
ATC Item
N/A
Pharmacotherapeutic Group
Antivirals for treatment of HIV infections, combinations
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| doravirine | N/A | doravirine |
| lamivudine | N/A | lamivudine |
| tenofovir disoproxil fumarate | N/A | tenofovir disoproxil fumarate |
EMA Name
Delstrigo
Medicine Name
Delstrigo
Aliases
N/ANo risk management plan link.
